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Available online 5 July 2016Objectives: This study aimed to investigate mirtazapine-induced changes in responsive neurostimulator (RNS)
recordings in a patient with epilepsy.
Materials andmethods: Cortical detection/stimulation counts from anRNS implanted in a patientwith bitemporal
epilepsy were matched to mirtazapine use to see if that drug altered hippocampal excitability.
Results: Mirtazapine decreased hippocampal stability; when mirtazapine was held after a washout period, DSC
counts declined, but when it was retrialed, DSC counts increased. Responsive epilepsy neurostimulator system
data helped design an optimal and individualizedmedication regimen for our patient with drug-resistant focal ep-
ilepsy.
Conclusions: Responsive neurostimulator systems in epilepsy may assess a medication's effect on hippocampal
excitability. Mirtazapine worsened hippocampal excitability in a patient with bitemporal epilepsy.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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In clinical trials, the RNS system (NeuroPace, Mountain View, CA)
was shown to signiﬁcantly reduce self-reported seizure frequencies in
patients with drug-resistant focal epilepsy [1]. The RNS does so by sur-
veying the electrocorticogram, speciﬁcally recognizing physician-
selected patterns of neural activity associated with seizure onset,
which, in turn, trigger electrical stimulation(s) or "therapies" designed
to help mitigate or hopefully terminate the electrical abnormalities al-
ready underway.
Outcomes of the RNS clinical trial relied on patient diaries of seizure
events [1]. Self-reported seizure frequencies remain amediocre yardstick
from which most epilepsy therapies are judged. Seizure events that
corrupt memory circuits, e.g., seizures of temporal lobe origin or brief
runs of asymptomatic spike-and-wave discharges, result in under-
counting [2]. We need ways to objectively count seizure frequencies
that do not rely on self-reporting.
If correctly programmed and electrodes are appropriately placed,
detection/stimulation counts (DSCs) can be considered as potential
markers of abnormal cortical excitability. An enabled RNS detects ab-
normal activity and delivers stimuli that records that twinned response
as an event. Events can then be reviewed on an hourly, daily, ormonthly
basis. Contemporary RNS programming detects and delivers therapies
generously. In the open-label portion of the RNS pivotal trial that
meant an average of 1175 DSCs per day [1, personal communication].50 17th Ave, Suite 540, Seattle,
oherty).
. This is an open access article underTherapies may target benign interictal patterns or alternatively termi-
nate early ictal patterns before a clinical seizure occurs. Individualizing
approaches to epilepsy management where self-reported seizure
counts are enhancedwith DSCmay suggest the need for RNS ormedical
therapies that are either useful or counterproductive. In one case report
of a patient with an RNS system, treating physicians were able to iden-
tify weekend caffeine consumption as a potential reason for increased
detections [3]. This case report sets out to document one way we were
able to use DSC to alter decisions involved in medical therapy.
2. Materials and methods
With informed patient consent, patient data were abstracted from
electronicmedical records including RNS logs of DSC. AverageDSC counts
by time of day were graphed for three different 6-day epochs:ﬁrst, when
mirtazapine was regularly used; second, during a postwashout period
where mirtazapine was not used; and third, when mirtazapine was
retrialed (Fig. 1).
3. Case report
A 45-year-old female with drug-resistant bitemporal epilepsy
underwent implantation of the RNS device in 2014 after failure of
medical and VNS therapies. Seizure types include audiogenic (Johnny
Cash's song Ring of Fire, for instance, would trigger focal seizures and po-
tentially convulsions). A brother and a second cousin also have epilepsy,
however her LG1 gene status is unknown. Comorbid conditions include
type I diabetes mellitus, depression, and insomnia. Her RNS detections
were recorded from two four-contact depth electrodes placed over thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Average detection/stimulation counts (DSCs) by time of day (h). Blue, series one, refers to six-day averagedetection (January 1–6) on full-dosemirtazapine. Red, series two, refers to
six-day average off ofmirtazapine and trazodone (January 11–12 and 15–18; trazodonewas takenon January 13–14prior to bedtime). Green, series three, refers to six-day average back to
full-dose mirtazapine (January 19–24).
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tracranialmonitoring results suggesting hippocampal involvement in sei-
zure generation. Her vagus nerve stimulator, which historically produced
no effect on seizure controls,was in the off position. A functional inslumin
pump was used for the duration studied.
Prior to this study period, depression and insomnia issues worsened.
Trazodone was initially tried, and although depressive symptoms im-
proved, she lacked motivation and energy. She was switched to 15-mg
of mirtazapine at night because it is mildly sedating and may boost
mood. However, when on mirtazapine, the patient complained of wors-
ening nighttime anxiety. Her RNS system was interrogated; histograms
of DSC by hour suggested far higher counts during sleeping hours than
during wakeful hours while the patient was on mirtazapine (Fig. 1).
Two therapy changes occurred,ﬁrst— a small lowering of her RNS output
current (from 4 mA to 3.5 mA) back to historical settings where her sei-
zure controls were thought to be better and second — a taper of
mirtazapine. Mirtazapine doses were weaned over several days, and
DSCs were assessed for a six-day period a week after discontinuation of
mirtazapine. Six nonconsecutive nights out of eight without mirtazapine
were recorded (for two consecutive nights, the patient used trazodone as
a sleep aid, those nights were not studied). Mirtazapine was then
reintroduced at full strength and six additional days of DSC counts
assessed to see if drug retrial had a reproducible change in DSC. All
other antiseizure medication doses during this time were kept the
same. Data appear in Fig. 1.4. Discussion
Mirtazapine is an atypical antidepressant with effects on noradrener-
gic, serotonin, norepinephrine, and histamine neurotransmission. It
reaches peak dose within 2 h and has an elimination half-life of 20–40 h
and a steady state by day ﬁve [4]. Mirtazapine was recently reported to
contribute to nonconvulsive status epilepticus in three patients [5]. In
these patients, the use of mirtazapine corresponded to more frequent
nocturnal DSC. We stopped mirtazapine with the assumption that themedication was altering seizure thresholds. This important clinical data
would not have been available to us without the RNS system.
The purpose of reporting this case is not to implicate mirtazapine as
a dangerous medication for patients with epilepsy. Instead, individual-
ized and very speciﬁc DSC data show that mirtazapine may have con-
tributed to nocturnal or sleep-related hippocampal excitability.
Whether this is perhaps a mechanism by which mirtazapine works for
mood or sedation is unknown. Clinically, mirtazapine use in this patient
worsened anxiety. Responsive neurostimulator data can be effectively
used beyond just delivering focal therapies based on recognition of ab-
normal cortical patterns. A concession could be the therapy changes in-
stituted by lowering RNS output currents might also change DSC,
though the retrial of mirtazapine and recurrence of higher DSC argues
against this.
With time, clinical implications of DSC alterations should become
clariﬁed. The most obvious one would be in the use of conventional anti-
seizure drugs (ASDs). In this patient, for instance, the use of a higher
nighttime and lowered daytime ASDs might decrease night events
and minimize the mood blunting effects of ASD therapies during the
day. Responsive neurostimulator programming teams could incorpo-
rate similar strategies in reviewing psychoactive medication problems
or successes. To avoid confounding, we found that medication DSC cor-
relations probably should be independent of periods where major RNS
system therapy changes aremade and thatmedicationwashout and re-
trials may be of use to conﬁrm speciﬁcity of medication effects on DSC.
Responsive neurostimulator device designs and usability teamsmay
wish to consider ways to make DSC data easy to visualize for RNS pro-
gramming teams. In this case, abstracting the DSC by hour and date
was not particularly straightforward and required assistance from the
RNS/NeuroPace team.
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